ASAtsushi Suzuki

Atsushi Suzuki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Atsushi Suzuki has a total of 93 co-authors. Here are the top co-authors by number of shared publications:

  • Junichi Yamaguchi

    Department of Cardiology, Tokyo Women's Medical University, 8-1 Kawada-cho Shinjuku-ku, Tokyo, 162-8666, Japan

    5 shared publications
  • Nobuhisa Hagiwara

    Department of Cardiology, Tokyo Women's Medical University, Tokyo, Japan

    5 shared publications
  • Tsuyoshi Shiga

    Department of Cardiology, Tokyo Women's Medical University, 8-1 Kawada-cho Shinjuku-ku, Tokyo, 162-8666, Japan

    5 shared publications
  • Ayano Yoshida

    Department of Cardiology, Kindai University, Osaka, Japan

    4 shared publications
  • Kyomi Ashihara

    Department of Cardiology, Tokyo Women's Medical University, 8-1 Kawada-cho Shinjuku-ku, Tokyo, 162-8666, Japan

    3 shared publications
  • Noriko Kikuchi

    Department of Cardiology, Tokyo Women's Medical University, 8-1 Kawada-cho Shinjuku-ku, Tokyo, 162-8666, Japan

    3 shared publications

Latest Publications

  • Open Access

    Coordinated decrease in plasma citrate and related organic acids during longitudinal follow-up in patients with cardiovascular risk factors: an exploratory metabolomic pilot study

    by Atsushi Suzuki, Kayoko Sato

    Objective: Comprehensive metabolomic profiling can reveal changes in metabolic state that are not apparent from routine clinical measurements. We explored how the plasma metabolome of patients with cardiovascular risk factors changes over approximately 1 year, during which the clinical picture remained stable, and we examined whether any observed changes were biological or technical in origin. Results: Eight patients (four men and four women; median age 62 years) were assessed at baseline and after a median of 334 days. No anthropometric or routine laboratory variable changed consistently across both statistical tests or after adjustment for multiple comparisons. Of 260 plasma metabolites, 37 differed between the two time points at an unadjusted P value below 0.05, of which 35 decreased; none remained significant after false discovery rate correction. Thirteen metabolites showed consistent nominal decreases across all analyses, including tricarboxylic acid cycle intermediates (citrate, malate), tartrate, lysophosphatidylcholines, and acylcarnitines. The change in citrate correlated with the changes in glycerol-3-phosphate, lactate, and tartrate. These changes were pathway-selective and unrelated to sample storage, sampling interval, or clinical variables. The findings are exploratory and identify candidate metabolites for confirmatory longitudinal studies.

  • Reply to “TAPSE/PASP Ratio as a Prognostic Marker in HFmrEF: A Missed Opportunity?”

    by Manami Ono, Yurika Fukunaga, Atsushi Suzuki, Shota Shirotani, Asaka Mikami, Arisa Nokubo, Makoto Kishihara, Toshiharu Koike, Eiji Shibahashi, Yoshiaki Minami, et al.

  • Prognostic significance of right ventricular–pulmonary artery coupling assessed by TAPSE/PASP ratio in patients with HFmrEF

    by Manami Ono, Yurika Fukunaga, Atsushi Suzuki, Shota Shirotani, Asaka Mikami, Arisa Nokubo, Makoto Kishihara, Toshiharu Koike, Eiji Shibahashi, Yoshiaki Minami, et al.

    Right ventricular–pulmonary artery (RV–PA) coupling is an indicator of the degree to which the right ventricle can adapt to afterload. The ratio of tricuspid annular plane systolic excursion (TAPSE) to pulmonary artery systolic pressure (PASP) (TAPSE/PASP ratio) has been proposed as a non-invasive measure of RV–PA coupling. RV–PA coupling is a key prognostic predictor of heart failure (HF); however, HF with mildly reduced left ventricular ejection fraction (HFmrEF) is difficult to predict. This study aimed to determine the prognostic significance of the TAPSE/PASP ratio in HFmrEF. This retrospective cohort study selected eligible patients from two previous cohorts of patients who were hospitalized for HF and discharged with HFmrEF diagnosed by echocardiography: one cohort from August 2015 to September 2019 and one from April 2020 and March 2023. The primary indicator was the TAPSE/PASP ratio, and the primary endpoint was a composite of all-cause mortality and HF rehospitalization. Patients were categorized into two groups based on the median TAPSE/PASP ratio, and the high and low TAPSE/PASP ratio groups were compared. Multivariate analysis was performed using the Cox proportional hazards model. This study included 391 patients (median age, 72 [60–80] years; 70% male). The median TAPSE/PASP ratio used as a cut-off was 0.54 mm/mmHg. The low TAPSE/PASP group was older (median age, 75 [67–82] vs. 68 [56–77] years, p < 0.001), had fewer men (65% vs. 76%, p = 0.019), and had higher B-type natriuretic peptide levels (267 [135–629] vs. 161 [54–394] pg/mL, p = 0.005) than the high TAPSE/PASP group. A significantly greater proportion of the low TAPSE/PASP group had atrial fibrillation (49% vs. 32%, p < 0.001) and renal dysfunction (estimated glomerular filtration rate, 46 [26–66] vs. 58 [32–76] mL/min/1.73 m2, p = 0.003) compared with the high TAPSE/PASP group. The low TAPSE/PASP group showed significantly higher rates of all-cause mortality and HF rehospitalization than the high TAPSE/PASP group (log-rank p < 0.001). Multivariate analysis confirmed that a TAPSE/PASP ratio < 0.54 mm/mmHg was an independent predictor of the primary endpoint (hazard ratio, 2.242; 95% confidence interval, 1.492–3.370; p < 0.001). At the one-year post-discharge follow-up, patients in the low TAPSE/PASP group were more likely to have inadequate recovery of RV–PA coupling than those in the high TAPSE/PASP group. The TAPSE/PASP ratio is a useful non-invasive prognostic indicator in patients with HFmrEF. This ratio may contribute to early risk stratification and treatment decision-making.


  • Metabolome analysis in patients with heart failure and implantable cardioverter defibrillators

    by Atsushi Suzuki, Tsuyoshi Shiga, Kayoko Sato, Morio Shoda, Junichi Yamaguchi

    Heart failure (HF) is a complex, heterogeneous syndrome with several comorbidities, often life-threatening and requires urgent therapy. In HF, metabolic alterations that can be assessed using comprehensive plasma, and tissue profiling will help establish new biomarkers and therapeutic targets. Metabolomic analysis of sudden death in HF cases remains unresolved. We prospectively evaluated 19 patients who underwent implantable cardioverter defibrillator (ICD) placement for the primary prevention of sudden cardiac death (SCD). Metabolomic analysis was performed using plasma samples before ICD implantation. Ventricular arrhythmia (VA)/SCD was defined as VA with an appropriate ICD therapy or SCD. During a median follow-up of 29 months (range, 13–35 months), four patients developed VA and one patient developed SCD. Using metabolomic analysis, arginine, lysine, and valine were significantly reduced in patients with VA/SCD (n = 5) compared with those without VA/SCD (n = 14). The molecules involved in energy metabolism might be associated with VA/SCD, thus requiring further investigation as a predictive value of metabolomic analysis of VA/SCD.


  • Open Access

    Correction: Prognostic factors in patients with heart failure and sarcopenia: an observational retrospective study

    by Yasutaka Imamura, Atsushi Suzuki, Kazuho Kamishima, Kazuhito Suzuki, Junichi Yamaguchi

  • Open Access

    Prognostic factors in patients with heart failure and sarcopenia: an observational retrospective study

    by Yasutaka Imamura, Atsushi Suzuki, Kazuho Kamishima, Kazuhito Suzuki, Junichi Yamaguchi

    Background: Heart failure (HF) prevalence increases with age, and sarcopenia is a poor prognostic factor in patients with HF. We aimed to evaluate the characteristics and prognostic factors in patients with HF and sarcopenia. Results: We retrospectively reviewed 256 consecutive patients admitted to our hospital for HF between May 2018 and May 2021, underwent dual-energy X-ray absorptiometry, and were diagnosed with sarcopenia. The primary endpoint was all-cause mortality. The prognoses and characteristics were evaluated and compared between patients with left ventricular ejection fraction (LVEF) < 50% (reduced LVEF, HF with reduced ejection fraction [HFrEF]) and those with LVEF ≥ 50% (preserved LVEF, HF with preserved ejection fraction [HFpEF]). 83 (32%) and 173 (68%) patients had HFrEF and HFpEF, respectively. The HFrEF group had fewer women, lower hypertension rates, higher ischemic heart disease rates, and brain natriuretic peptide (BNP) levels than did the HFpEF group. Kaplan–Meier analysis for all-cause death showed that the HFrEF group had a significantly worse prognosis than the HFpEF group [log-rank p = 0.002]. Conclusions: In patients with HF and sarcopenia, older age, higher New York Heart Association (NYHA) class, BNP levels, and reduced LVEF were independent predictors of death after evaluation. During the treatment of patients with HF and sarcopenia, it is necessary to manage treatment with close attention to BNP and LVEF.


  • Prognostic Impact of Landiolol in Patients with Acute Heart Failure and Atrial Fibrillation with Rapid Ventricular Rates: A Pilot Observational Study

    by Shota Shirotani, Kentaro Jujo, Takuro Abe, Motoko Kametani, Yuichiro Minami, Atsushi Suzuki, Tsuyoshi Shiga, Nobuhisa Hagiwara

    Introduction: Guidelines recommend ventricular rate control to Methods: This observational study included 60 patients who were urgently hospitalized with ADHF and presented with AF and a heart rate (HR) ≥130 bpm at admission. The patients were assigned to the landiolol group (n = 37) or the reference group (n = 23) based on their intravenous landiolol use within 24 h after admission. The primary endpoint was death from any cause. Results: The groups’ baseline characteristics were similar. A significant HR reduction occurred in the landiolol group at 2 h after admission. Compared with the reference group, the HR was significantly lower (111.6 vs. 97.9 bpm, p = 0.02) and the absolute HR reduction was greater (−32.2 vs. −50.0 bpm, p = 0.006) in the landiolol group at 48 h after admission. The landiolol group’s mortality rate was significantly lower than that in the reference group (log-rank test, p = 0.032). landiolol use within 24 h after admission was independently associated with lower all-cause mortality (adjusted hazard ratio: 0.15, 95% confidence interval: 0.02–0.92). Conclusion: Patients with ADHF and AF who received landiolol for rate control during the acute phase had better prognoses than those who did not receive landiolol.


  • Acute decompensated heart failure in a patient with primary aldosteronism successfully treated with an adrenalectomy: A case report

    by Yasutaka Imamura, Atsushi Suzuki, Michiru Nomoto, Mayu Takano, Shintaro Sawa, Ryogo Hoki, Noriko Kikuchi, Yusaku Yoshida, Kenta Uto, Hiroshi Niinami, et al.